Clinical Associate Professor, Dr David Sullivan
Accelerated development of novel lipid-lowering therapies based on genetics
High cholesterol contributes to over a third of coronary heart disease burden. Despite well-established evidence supporting the benefits of cholesterol lowering for the prevention of cardiovascular disease (CVD), many patients fail to meet their lipid targets.
Mendelian Randomization, a Precision Medicine technique which allows the identification of causal risk factors and therapeutic targets, has greatly accelerated the development of lipid-lowering agents which are capable of improving cardiovascular outcomes and preventing some cases of acute pancreatitis. One agent may reduce the progression of aortic stenosis.
Dr Sullivan's presentation will outline the bioinformatic process of Mendelian Randomization and introduce several successful applications of its use to treat hypercholesterolaemia, hypertriglyceridaemia and elevated levels of Lipoprotein (a).
Mendelian Randomization, a Precision Medicine technique which allows the identification of causal risk factors and therapeutic targets, has greatly accelerated the development of lipid-lowering agents which are capable of improving cardiovascular outcomes and preventing some cases of acute pancreatitis. One agent may reduce the progression of aortic stenosis.
Dr Sullivan's presentation will outline the bioinformatic process of Mendelian Randomization and introduce several successful applications of its use to treat hypercholesterolaemia, hypertriglyceridaemia and elevated levels of Lipoprotein (a).
|
Dr David Sullivan is a physician / chemical pathologist in the Department of Chemical Pathology at Royal Prince Alfred Hospital and an Associate Professor, Faculty of Medicine at the University of Sydney Central Clinical School.
David has a long-term interest in lipid metabolism with particular emphasis on the environmental component (especially dietary) of gene – environment interactions contributing to cardiovascular disease. He has been involved in the early use of many forms of lipid-lowering intervention. He supports the improvement of detection and management of severe inherited dyslipidaemia, such as that seen in Familial Hypercholesterolaemia. David has experience in several international clinical posts, including World Health Organization (WHO) Fellowship at the MRC Lipoprotein Unit, Royal Postgraduate School of Medicine, Hammersmith Hospital, London. He co-ordinated international clinical studies from the WHO reference lipid laboratory in Wageningen, Netherlands where he worked with the originator of the technique known as Mendelian Randomisation. In addition to his clinical and teaching activities, he has served on numerous clinical committees including the management committees of the LIPID and FIELD trials. Current research interests include biomarkers and post-prandial metabolism. |
|
Pharmacy Guild of Australia,
Tasmanian Branch Level 2, 38 Montpelier Retreat Battery Point TAS 7004 |
Ph: 03 6220 2955
Fax: 03 6220 2966 Email: guild.tas@guild.org.au |
|